The wearable-ring maker's roadshow values it as high as $15 billion. Look at the filing's own use-of-proceeds section, and the company itself is barely raising any money at all.
Oura, the maker of a popular health-tracking ring, launched its IPO roadshow this week with shares expected to price between $40 and $44, a range that implies a fully diluted valuation of roughly $15 billion. Cornerstone investors have lined up non-binding indications of interest, including up to $100 million from Eli Lilly and up to $300 million from funds affiliated with Dragoneer Investment Group.
The headline valuation obscures a more revealing detail buried in the filing's use-of-proceeds section. Of the roughly $567 million in gross proceeds attributable to Oura's own newly issued shares at the midpoint of the range, the company says it plans to direct approximately $526.4 million toward covering accumulated tax obligations tied to employee stock grants, leaving the company itself with roughly $6.2 million for general corporate purposes. In other words, the overwhelming majority of what looks like a capital raise is, functionally, a tax bill.
That detail sharpens a structural feature of the offering that was already visible in its share count: nearly three-quarters of the shares being sold in the IPO belong to existing investors and employees cashing out, not to the company issuing new stock. Early backer Forerunner Ventures, the filing indicates, is selling its entire stake, a position that traces back to a $28 million Series B investment in 2020 and is now worth roughly $1.2 billion at the midpoint of the offering range. Fidelity Investments, by contrast, is Oura's largest shareholder and is selling none of its position, while sovereign investor Temasek and venture firms ICONIQ Capital and Atreides are described as selling little to nothing.
The contrast between Fidelity's decision to hold and Forerunner's decision to sell its entire position is, in its own way, the most useful data point in the filing: two large, sophisticated holders looking at the same company and the same offering price, reaching opposite conclusions about whether now is the time to exit. For a company whose own primary offering nets it next to nothing after employee tax obligations, that split verdict from its own cap table may tell investors more about the durability of Oura's growth story than the valuation headline does.